Why the study?
Does substrate-based VT ablation reduce VT burden and ICD therapies?
Does substrate-based VT ablation reduce VT burden and ICD therapies?
Substrate-based VT ablation effectively reduces overall VT burden and ICD therapies, although long-term recurrence remains high, particularly in patients with lower EF and persistent late potentials.
May reduce VT burden and ICD therapies; leaves open confirmation of benefit and role of EF/late potentials in randomized trials.
Despite a high recurrence rate during long-term follow-up, substrate-based VT ablation is related to a large reduction in VT burden and a decrease in ICD therapies. Lower EF and persistence of late potentials are predictors of recurrence.
No takes yet. Share an insight, caveat, or question.
Quinto et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: